Protagenic Therapeutics Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
PTIX
- Investments
-
1
- Share Price
-
$0.42
- (As of Wednesday Closing)
Protagenic Therapeutics General Information
Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Contact Information
Website
www.protagenic.comCorporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
Corporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
Protagenic Therapeutics Stock Performance
As of 18-Nov-2026, Protagenic Therapeutics’s stock price is $0.42. Its current market cap is $760K with 1.81M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.42 | $0.46 | $0.13 - $2.38 | $760K | 1.81M | 12.6K | $2.33 |
Protagenic Therapeutics Financials Summary
As of 30-Sep-2026, Protagenic Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|---|
| EV | 900 | 3,010 | (370) | 2,444 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | 6,976 | 2,912 | (2,553) | (5,519) |
| Net Income | 5,664 | 1,368 | (3,592) | (5,525) |
| Total Assets | 2,272 | 3,650 | 1,956 | |
| Total Debt | 0 | 0 | 0 | 0 |
Protagenic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Protagenic Therapeutics Comparisons
Industry
Financing
Details
Protagenic Therapeutics Competitors (17)
One of Protagenic Therapeutics’s 17 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Lamassu | Venture Capital-Backed | Durham, NC | ||||
| Calliditas Therapeutics France | Corporate Backed or Acquired | Saint-Julien- en-Genevois, France | ||||
| Hansa Biopharma | Corporation | Lund, Sweden | ||||
| Omeros | Formerly VC-backed | Seattle, WA |
Protagenic Therapeutics Patents
Protagenic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2960804-T3 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for the treatment of opioid addiction | Active | 13-Mar-2018 | ||
| CA-3093841-A1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Pending | 13-Mar-2018 | ||
| EP-3765056-A1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | ||
| EP-3765056-B1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | ||
| EP-3765056-C0 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | A61K38/17 |
Protagenic Therapeutics Signals
Protagenic Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Protagenic Therapeutics Acquisitions (1)
Protagenic Therapeutics’s most recent deal was a Merger/Acquisition with Atrinsic. The deal was made on 12-Feb-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Atrinsic | 12-Feb-2016 | Merger/Acquisition | Media and Information Services (B2B) |
Protagenic Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Protagenic Therapeutics FAQs
-
When was Protagenic Therapeutics founded?
Protagenic Therapeutics was founded in 1994.
-
Where is Protagenic Therapeutics headquartered?
Protagenic Therapeutics is headquartered in New York, NY.
-
What is the size of Protagenic Therapeutics?
Protagenic Therapeutics has 3 total employees.
-
What industry is Protagenic Therapeutics in?
Protagenic Therapeutics’s primary industry is Drug Discovery.
-
Is Protagenic Therapeutics a private or public company?
Protagenic Therapeutics is a Public company.
-
What is Protagenic Therapeutics’s stock symbol?
The ticker symbol for Protagenic Therapeutics is PTIX.
-
What is the current stock price of Protagenic Therapeutics?
As of 18-Nov-2026 the stock price of Protagenic Therapeutics is $0.42.
-
What is the current market cap of Protagenic Therapeutics?
The current market capitalization of Protagenic Therapeutics is $760K.
-
Who are Protagenic Therapeutics’s competitors?
ACADIA Pharmaceuticals, Lamassu, Calliditas Therapeutics France, Hansa Biopharma, and Omeros are some of the 17 competitors of Protagenic Therapeutics.
-
What is Protagenic Therapeutics’s annual earnings per share (EPS)?
Protagenic Therapeutics’s EPS for 12 months was $2.33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process